What is the role of secondary venous thromboembolism prophylaxis in antiphospholipid syndrome (APS)?

By William Aird

EULAR recommendations for the management of antiphospholipid syndrome in adults:

2021 Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report:

Regarding the use of DOACs in APS:

  • If a patient with triple-positive antiphospholipid syndrome (APS) presents with VTE, then VKA is favored over DOAC therapy. If such a patient is initiated on a DOAC, then panel consensus exists for transitioning to VKA therapy.

Learn more here.